AlphaMedix by Orano Med for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval

AlphaMedix is under clinical development by Orano Med and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).

Apr 23, 2024 - 00:00

AlphaMedix is under clinical development by Orano Med and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).

Read the original article

Tags:

Previous Article

Farletuzumab ecteribulin by Eisai for Ovarian Cancer: Likelihood of Approval

Lorcaserin hydrochloride by EpyGenix Therapeutics for Dravet Syndrome (Severe My...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Me...

Jul 1, 2023

Opinion: The complicated connections between weight loss drugs and mental health

Opinion: The complicated connections between weight los...

Feb 19, 2024

RSV monoclonal Beyfortus was 90% effective at preventing hospitalizations in children this winter: CDC

RSV monoclonal Beyfortus was 90% effective at preventin...

Mar 8, 2024